India Pesticides Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 16 Jul 2026 | Fertilizers & Agrochemicals | Market Cap: ₹1.6K Cr
FY27 revenue growth is expected around 20% over FY26. India Pesticides expects about 20% revenue growth in FY27 over FY26.
From India Pesticides Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹140
Market Cap
₹1.6K Cr
P/E Ratio
15.0
How does India Pesticides Ltd rank in Fertilizers & Agrochemicals?
Compare India Pesticides Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
India Pesticides Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹266 Cr, net profit ₹32 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY27 revenue growth is expected around 20% over FY26.
- →EBITDA margin guidance for FY27 remains in the 18% to 20% range.
- →The roadmap aims to reach INR 3,000 crores in revenue by FY31.
- →Revenue contribution by FY31 is expected to be:
- → - INR 1,000-1,100 crores from Hamirpur facility.
- → - INR 1,500 crores from existing technical facilities (Sandila and Dewa Road).
- → - INR 500 crores from the B2C branded segment.
- →Shalvis facility is projected to contribute INR 80-100 crores in FY27 and is expected to scale up to INR 1,000 crores in revenue over 5 years.
- →Capacity expansions are ongoing, targeting about 29,000 metric tons in near term with further additions planned.
- →Expanded registrations and new product launches both domestically and internationally will support growth.
- →Stable pricing and volume increases expected to support revenue growth.
📈 Profitability & Margins
- →India Pesticides expects about 20% revenue growth in FY27 over FY26.
- →EBITDA margin guidance for FY27 remains stable at 18% to 20%.
- →Net profit for 9M FY26 increased by 44% YoY to INR89 crores, indicating strong operating leverage.
- →Capacity expansions at existing and new facilities (Hamirpur, Sandila, Shalvis) are planned to support growth.
- →The Hamirpur plant is expected to contribute INR1,000-1,100 crores, existing units INR1,500 crores, and B2C segment INR500 crores by FY31.
- →Expansion and new registrations in export markets (Australia, New Zealand, Europe) are expected to add incremental revenues (~INR10-15 crores).
- →Ongoing R&D and operational efficiencies aim to sustain margin improvements and cost competitiveness.
- →Overall, the company targets INR3,000 crores revenue by March 2031, signaling strong long-term growth in earnings and profitability.
🏗️ Capital Expenditure Plans
- →**Shalvis Facility:**
- → - Two blocks operational; second block expected ready by Aug-Sept 2026.
- → - Revenue potential of INR80-100 crores in FY27 from these blocks.
- → - Plans to add 2-3 blocks annually over next 3-4 years, targeting 10 blocks total.
- → - Expected to achieve INR1,000 crores revenue from Shalvis in 5 years.
- → - Capex for next year: INR80-100 crores.
- →**Sandila Unit:**
- → - Planned capex of INR25-30 crores for FY27 towards a technical plant and bulk formulation expansion.
- →**Hamirpur Facility:**
- → - Expected revenue of INR1,000-1,100 crores by March 2031 (capex details not specified).
- →**Funding:**
- → - Shalvis capex mostly funded by internal accruals, with INR25-30 crores from loans.
- → - Emphasis on phased capacity expansion aligned with visible demand.
- →**Other:**
- → - Investments in renewable energy (6 MW solar supply at Sandila unit).
- → - Continuous R&D leading to new molecule introductions and process optimizations.
💰 Fundraising & Capital Structure
- →For the Shalvis capex of INR80 to 100 crores planned next year, the company will fund mostly through internal accruals.
- →They plan to take some small loans of around INR25 to 30 crores for Shalvis expansion.
- →For the Sandila unit capex of INR25 to 30 crores, funding details were not specifically mentioned but implied to be from internal sources.
- →Overall, the company is planning to fuel its capex plans mostly with internal accruals.
- →No specific mention of any new equity fundraising was made during the call.
📋 Order Book & Pipeline
- →India Pesticides Limited is actively engaged in multiple ongoing projects under its CDMO business with clients from Japan, the USA, and Australia.
- →Discussions and site visits are progressing well, with positive client feedback and sample approvals already received.
- →The company has projects underway and expects materialization of these collaborations soon.
- →Several registrations are pending and in process: about 5 reports are being worked on for overseas and domestic submissions.
- →Recent registrations include fungicide formulation registrations in Australia, as well as registrations in Europe and New Zealand expected to bring incremental revenues.
- →The management expects to secure 7-8 overseas registrations in the coming year, along with a similar number pending with the Central Insecticides Board (CIB) in Delhi.
- →No specific quantitative data on total order book value was disclosed during the call.
Key Metrics
Frequently Asked Questions
What were India Pesticides Ltd Q3 FY26 results?
FY27 revenue growth is expected around 20% over FY26. India Pesticides expects about 20% revenue growth in FY27 over FY26.
What is India Pesticides Ltd share price analysis?
India Pesticides Ltd currently shows a neutral. The stock trades at a P/E of 15.0 with a market cap of ₹1,618 Cr. Investors should review the full earnings analysis for detailed insights.
Is India Pesticides Ltd planning capital expenditure?
Shalvis Facility:** - Two blocks operational; second block expected ready by Aug-Sept 2026.
Keep India Pesticides Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.